Clinical Observation on GP Combined Intravenation with Intraperitoneal Hyperthermic Perfusion Chemotherapy for Advanced Pancreatic Cancer

Objective 　To explore the effect of combined intravenation with intraperitoneal hyperthermic perfusion chemotherapy for the advanced pancreatic cancer. Methods 　Twenty2six patient s with advanced pancreatic cancer diagnosed by pathology were chosen as our subjects. Every subject was treated with the following regimen, administered every 21～28 days. 2500～3500 ml normal saline of 40 ℃ mixed with cisplatin 80～100 mg/ m² plus dexamethasone 10 mg plus furosemide 40mg were perfused by abdomen puncture, on d1 . Followed by Ringer 1500 ml plus STS 20～40 g by iv within 12 hours. And the next day, half dose of STS by iv within 12 hours also. Simultaneously gemcitabine 1. 0～1. 25 g/ m² by iv on d1, d8 . 21～28 days were 1 cycle, All the patient s received 4 cycles. And effect and toxicity were observed. Results 　Twenty-six cases could be evaluated according to Response Evaluation Criteria in Solid Tumors, the median survival time was 8 months. The total response rate was 38. 5 %, myelosuppression was the main toxicity. Non0hemotological toxicity was mild and tolerable. Conclusion 　The GP combined intravenation with int raperitoneal hyperthermic perfusion treatment is an effective regiment in the treatment of advanced pancreatic cancer, and we should study it further.